A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Source: EU CTIS · Data processed: Feb 4, 2026